EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Pharmacogenetic Predictors of Metformin Response in Metabolic Syndrome and Type 2 Diabetes: Evidence from a Cohort Study in Kazakhstan

Altynay T Imangaliyeva iD, Nurgul S Sikhayeva iD, Serik A Baidurin iD, Bibigul A Suleimenova iD, Aliya A Romanova iD, Elena V Zholdybayeva iD, Serik A Shaimerdenov iD, Aigul Sh Kuanysheva iD, Aidos Bolatov iD

Journal of Diabetes Research · 2025-01 · 2025 (1)

DOI: 10.1155/jdr/1568889 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of Diabetes Research, online erschienen am 26.09.2025. Verfasst von Altynay T Imangaliyeva und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine With Courses in Nephrology, Hematology, Allergology and Immunology, Astana Medical University, Astana, Kazakhstan. Hauptthemen laut MEDLINE: Metformin, Diabetes Mellitus, Type 2, Metabolic Syndrome, Hypoglycemic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) are highly prevalent in Kazakhstan, with metformin as the first‐line therapy. However, individual variability in treatment response and adverse effects necessitates pharmacogenetic evaluation. This study is aimed at assessing the clinical and biochemical efficacy of metformin in Kazakh patients with MetS, T2DM, or both and at identifying pharmacogenetic markers associated with treatment response and tolerability.

Methods

A prospective cohort of 206 Kazakh patients (MetS: n = 44, MetS + T2DM: n = 123, T2DM: n = 39) was enrolled. Clinical, anthropometric, and biochemical parameters were measured at baseline and 3 months after metformin therapy. Ten SNPs previously implicated in metformin pharmacogenetics were genotyped. Associations with treatment efficacy (HbA1c reduction and glycemic goal achievement) and dyspeptic side effects were analyzed using ANOVA, logistic regression, and chi‐square tests.

Results

Metformin significantly improved weight, blood pressure, glucose, and lipid profiles across all groups. The SNPs rs2289669 (SLC47A1) and rs3792269 (CAPN10) were significantly associated with greater HbA1c reduction, glycemic goal achievement, and risk of dyspepsia. The rs11212617 variant showed a modest association with treatment efficacy.

Conclusions

Metformin is effective across diverse metabolic phenotypes in the Kazakh population, with genetic variation contributing to interindividual differences in efficacy and tolerability. Pharmacogenetic profiling may improve personalized diabetes care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminDiabetes Mellitus, Type 2Metabolic SyndromeHypoglycemic AgentsHumansMaleFemaleMiddle AgedKazakhstanPolymorphism, Single NucleotideProspective StudiesTreatment OutcomeAdultBlood GlucoseAgedGlycated HemoglobinPharmacogenetics

Stichwörter der Autor:innen

KazakhstanType 2 diabetes mellitusmetabolic syndromemetforminpharmacogeneticsprecision medicine

Substanzen

MetforminHypoglycemic AgentsBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, human

Autor:innen und Institutionen

  • Department of Internal Medicine With Courses in Nephrology, Hematology, Allergology and Immunology, Astana Medical University, Astana, Kazakhstan.
  • National Center for Biotechnology, National Holding "Qazbiopharm", Astana, Kazakhstan.
  • Administration Unit, "Salauatty Astana" LLC, Astana, Kazakhstan.
  • Administration Unit, City Polyclinic №4, Astana, Kazakhstan.
  • Administration Unit, City Polyclinic №7, Astana, Kazakhstan.
  • Shenzhen University Medical School, Shenzhen University, Shenzhen, Guangdong, China.

ORCID-Profile: Altynay T Imangaliyeva, Nurgul S Sikhayeva, Serik A Baidurin, Bibigul A Suleimenova, Aliya A Romanova, Elena V Zholdybayeva, Serik A Shaimerdenov, Aigul Sh Kuanysheva, Aidos Bolatov

Zitieren

APA

Imangaliyeva, A. T., Sikhayeva, N. S., Baidurin, S. A., Suleimenova, B. A., Romanova, A. A., Zholdybayeva, E. V., Shaimerdenov, S. A., Kuanysheva, A. S., & Bolatov, A. (2025). Pharmacogenetic Predictors of Metformin Response in Metabolic Syndrome and Type 2 Diabetes: Evidence from a Cohort Study in Kazakhstan. Journal of Diabetes Research, 2025(1). https://doi.org/10.1155/jdr/1568889

Vancouver

Imangaliyeva AT, Sikhayeva NS, Baidurin SA, Suleimenova BA, Romanova AA, Zholdybayeva EV, et al. Pharmacogenetic Predictors of Metformin Response in Metabolic Syndrome and Type 2 Diabetes: Evidence from a Cohort Study in Kazakhstan. Journal of Diabetes Research. 2025;2025(1). doi:10.1155/jdr/1568889

BibTeX
@article{Imangaliyeva2025,
  author = {Imangaliyeva, Altynay T and Sikhayeva, Nurgul S and Baidurin, Serik A and Suleimenova, Bibigul A and Romanova, Aliya A and Zholdybayeva, Elena V and Shaimerdenov, Serik A and Kuanysheva, Aigul Sh and Bolatov, Aidos},
  title = {Pharmacogenetic Predictors of Metformin Response in Metabolic Syndrome and Type 2 Diabetes: Evidence from a Cohort Study in Kazakhstan},
  journal = {Journal of Diabetes Research},
  year = {2025},
  volume = {2025},
  number = {1},
  doi = {10.1155/jdr/1568889}
}
Kostenlos starten →